Although no benefit was observed in animals harboring IL-13Rα2-low HGG, IL-13Rα2-medium and IL-13Rα2-high animals had significantly reduced tumor burden and lived significantly longer than vehicle-treated animals, indicating IL-13Rα2 may not only be a therapeutic target but also a predictive biomarker for future clinical trial patient inclusion. The gene discussed is IL13RA2; the disease is neoplasm.